2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 539

Thyroid Function in Early Versus Established Rheumatoid Arthritis
Abstract Number: 1522

Time Dependent Effect of Biologic Therapy on Overall Survival in Patients with Rheumatoid Arthritis and Cancer
Abstract Number: 575

Time to Discontinuation of Biologic Therapy By Mechanism of Action in Rheumatoid Arthritis: Results from a Rheumatoid Arthritis Cohort
Abstract Number: 1011

Tissue Resident Macrophages Establish a Niche That Limits Monocyte to Macrophage Differentiation in Synovial Tissue during Homeostasis
Abstract Number: 448

Tizanidine, a Frequently Used Muscle Relaxant, Is Associated with Severe Hypotension: Role of Cytochrome P450 1A2 Inhibition in Routine Clinical Practice
Abstract Number: 692

TNF Inhibitor Dose Tapering in Axial Spondyloarthritis: A Systematic Review and Meta-Analysis
Abstract Number: 2625

TNF Inhibitor Reduces ASDAS Faster and More Stable in Ankylosing Spondylitis Patients: Results from a Real World Prospective Cohort Managed By Smart Phone System
Abstract Number: 233

TNF Inhibitors: Prevalence of Use and Predictors of Treatment Non-Persistence in the 2011-2016 Medicare Population
Abstract Number: 63

TNF-α Blockade Incompletely Reverses Inflammatory Pulmonary Pathology in the TNF-Transgenic Mouse Model of Rheumatoid Arthritis
Abstract Number: 1022

TNF-α Regulates Plasmacytoid Dendritic Cells By Suppressing IFN-α Production and Enhancing Th1 and Th17 Cell Differentiation
Abstract Number: 841

TNFR2 Inactivation Reduces Psoriatic Inflammation in Mice Via Down-Regulating Dendritic Cell Expansion and Inhibiting IL-23/IL-17 Pathways
Abstract Number: 2327

To Screen or Not to Screen?Dexa Ordering Patterns in SLE Patients Who Take Systemic Glucocorticoids
Abstract Number: 1216

To Study the Frequency of Persistent Arthritis, in Patients with Chikungunya Fever, in a Tertiary Health Care Center
Abstract Number: 767

Tobacco and Systemic Lupus Erythematosus Relationships: Pay Attention to the Retina!
Abstract Number: 958

Tocilizumab and the Risk for Cardiovascular Disease Events Among Rheumatoid Arthritis Patients: A Direct Comparison in Real World Setting

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].